Gland Pharma Limited has disclosed the appointment of Mr. Ajay Sahni as President of Phixen SAS, a wholly owned step-down subsidiary of the company. The appointment is effective from November 30, 2026.
Appointment Details
- Mr. Ajay Sahni replaces Mr. Alain Kirchmeyer as President of Phixen SAS
- Effective date: November 30, 2026
- Mr. Sahni will report to the CEO of Gland Pharma Limited
- This appointment follows his previous appointment as Chief Executive Officer of Gland Pharma International Pte. Ltd ('Gland Singapore') on October 30, 2026, where he is responsible for the Cenexi business
Executive Profile
Mr. Ajay Sahni brings over 36 years of experience in FMCG and pharmaceutical industries, with expertise in:
- Financial management
- Business development
- General management
Professional Background
Key previous roles include:
- Managing Director for Pinewood Healthcare Ltd, Ireland
- Managing Director for Wockhardt Bio AG, Switzerland
- President of Wockhardt France SAS and its subsidiaries
- Various roles at Sanofi SA, Sanofi Synthelabo Inc., Sanofi-Synthelabo Pte. Ltd, and Ferring Pharmaceuticals
- Work experience across France, Belgium, Ireland, Switzerland, Singapore, and USA
Educational Qualification
Mr. Sahni holds a Bachelor's degree in Business Administration from European University of Brussels, Belgium.
Company Contacts
The disclosure is signed by Mr. Sampath Kumar Pallerlamudi, Company Secretary and Compliance Officer of Gland Pharma Limited, from the company's registered office at Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal, Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India.
Financial Impact
No financial impact or compensation details are disclosed in this filing.